Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

SNSE

Sensei Biotherapeutics Inc

Last Close
May 03 • 04:00PM ET
1.79
Dollar change
+0.14
Percentage change
8.48 		%
Held by: VTI VXF IWC
Index- P/E- EPS (ttm)-1.21 Insider Own35.02% Shs Outstand25.03M Perf Week75.49%
Market Cap44.89M Forward P/E- EPS next Y-1.04 Insider Trans0.00% Shs Float16.30M Perf Month80.81%
Income-34.10M PEG- EPS next Q-0.27 Inst Own11.02% Short Float0.50% Perf Quarter120.99%
Sales0.00M P/S- EPS this Y19.37% Inst Trans-0.13% Short Ratio0.54 Perf Half Y118.29%
Book/sh2.59 P/B0.69 EPS next Y-5.23% ROA-35.38% Short Interest0.08M Perf Year19.33%
Cash/sh2.62 P/C0.68 EPS next 5Y- ROE-40.52% 52W Range0.51 - 1.92 Perf YTD158.67%
Dividend Est.- P/FCF- EPS past 5Y-16.26% ROI-49.66% 52W High-6.77% Beta0.12
Dividend TTM- Quick Ratio11.92 Sales past 5Y0.00% Gross Margin- 52W Low250.98% ATR (14)0.15
Dividend Ex-Date- Current Ratio11.92 EPS Y/Y TTM23.36% Oper. Margin0.00% RSI (14)86.99 Volatility21.42% 13.26%
Employees27 Debt/Eq0.10 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price4.67
Option/ShortNo / Yes LT Debt/Eq0.06 EPS Q/Q25.56% Payout- Rel Volume4.76 Prev Close1.65
Sales Surprise- EPS Surprise2.47% Sales Q/Q- EarningsFeb 28 BMO Avg Volume150.96K Price1.79
SMA2068.70% SMA5078.26% SMA200105.10% Trades Volume718,167 Change8.48%
Date Action Analyst Rating Change Price Target Change
Jul-01-21Downgrade Berenberg Buy → Hold $12
Jun-29-21Downgrade Oppenheimer Outperform → Perform $30 → $14
Mar-01-21Initiated Piper Sandler Overweight $25
Mar-01-21Initiated Oppenheimer Outperform $36
Mar-01-21Initiated Citigroup Buy $30
Mar-01-21Initiated Berenberg Buy $27
Apr-24-24 04:05PM
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
(GlobeNewswire)
Apr-09-24 07:30AM
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
(GlobeNewswire) +6.28%
Apr-04-24 04:05PM
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
(GlobeNewswire)
Mar-22-24 07:30AM
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
(GlobeNewswire) +11.43%
Mar-06-24 07:30AM
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
(GlobeNewswire)
07:30AM Loading…
Feb-28-24 07:30AM
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
(GlobeNewswire) +9.09%
Feb-07-24 07:30AM
Sensei Biotherapeutics to Present at Upcoming Conferences
(GlobeNewswire) +6.12%
Jan-04-24 07:30AM
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
(GlobeNewswire)
Nov-07-23 08:09AM
Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Results
(GuruFocus.com) -7.15%
07:30AM
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
(GlobeNewswire)
Nov-03-23 04:05PM
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
(GlobeNewswire) -13.75%
Nov-01-23 07:30AM
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
(GlobeNewswire) +15.33%
Oct-25-23 09:05AM
Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
(GlobeNewswire)
Oct-23-23 07:30AM
Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
(GlobeNewswire)
Sep-27-23 07:30AM
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron s Libtayo
(GlobeNewswire) -10.17%
07:30AM Loading…
Sep-21-23 07:30AM
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
(GlobeNewswire)
Sep-13-23 07:30AM
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
(GlobeNewswire)
Aug-30-23 07:30AM
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-19-23 10:44AM
Billionaire Stan Druckenmillers Small-Cap Stock Picks
(Insider Monkey)
Aug-03-23 07:30AM
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
(GlobeNewswire)
Aug-02-23 07:30AM
Sensei Biotherapeutics to Participate in Canaccord Genuitys 43rd Annual Growth Conference
(GlobeNewswire)
Jun-13-23 07:30AM
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, A New Vista for Cancer Care: Exploring SNS-101s Potential as a Transformative Treatment Option for Patients with Solid Tumors
(GlobeNewswire)
Jun-01-23 07:30AM
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors
(GlobeNewswire)
May-31-23 07:30AM
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
(GlobeNewswire)
May-09-23 07:30AM
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
(GlobeNewswire)
Apr-20-23 07:30AM
Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody
(GlobeNewswire)
Apr-18-23 04:05PM
Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023
(GlobeNewswire)
Apr-13-23 07:30AM
Sensei Biotherapeutics to Participate in Canaccord Genuitys Horizons in Oncology Virtual Conference
(GlobeNewswire)
Mar-30-23 07:30AM
Sensei Biotherapeutics to Participate in Cantor Fitzgeralds Future of Oncology Virtual Symposium
(GlobeNewswire) +6.11%
Mar-28-23 07:30AM
Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights
(GlobeNewswire)
11:56AM Loading…
Mar-23-23 11:56AM
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
(Simply Wall St.)
Mar-21-23 07:30AM
Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody
(GlobeNewswire)
Mar-14-23 04:35PM
Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023
(GlobeNewswire) +9.92%
Mar-07-23 05:15PM
Sensei Biotherapeutics Adopts Stockholder Rights Agreement
(GlobeNewswire) +6.49%
Mar-06-23 07:30AM
Sensei Biotherapeutics to Participate in Oppenheimers 33rd Annual Healthcare Conference
(GlobeNewswire)
Feb-21-23 07:30AM
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
(GlobeNewswire) -7.14%
Feb-16-23 07:30AM
Sensei Biotherapeutics to Participate in Citis 2023 Virtual Oncology Leadership Summit
(GlobeNewswire)
Feb-14-23 07:30AM
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
(GlobeNewswire)
Feb-06-23 07:30AM
Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody
(GlobeNewswire)
Jan-05-23 07:30AM
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors
(GlobeNewswire)
Dec-08-22 01:10PM
Immunotherapy startup shutters Boston research site, lays off 17
(American City Business Journals)
10:40AM
Sensei Biotherapeutics Slashes Workforce, Closes R&D Site
(Benzinga)
07:30AM
Sensei Biotherapeutics Provides Update on Strategic Priorities
(GlobeNewswire)
Nov-22-22 07:30AM
Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
(GlobeNewswire)
Nov-21-22 07:30AM
Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody
(GlobeNewswire)
06:00AM
Significant Investor in Sensei Biotherapeutics, Inc. Urges Board to Seek Shareholder Mandate
(GlobeNewswire)
Nov-10-22 09:00AM
Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
(GlobeNewswire) +9.49%
Nov-08-22 07:30AM
Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
(GlobeNewswire)
Nov-07-22 07:30AM
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint
(GlobeNewswire)
Nov-02-22 07:30AM
Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
(GlobeNewswire)
Oct-14-22 10:22AM
We're Keeping An Eye On Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Rate
(Simply Wall St.)
Oct-05-22 08:05AM
Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
(GlobeNewswire)
Sep-30-22 04:05PM
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
(GlobeNewswire)
Sep-21-22 04:05PM
Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
(GlobeNewswire) -5.32%
Aug-31-22 07:30AM
Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody
(GlobeNewswire)
Aug-23-22 07:30AM
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-11-22 07:02AM
One Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insider upped their stake by 13% in the previous year
(Simply Wall St.)
Aug-09-22 07:30AM
Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
(GlobeNewswire) -5.37%
Jun-01-22 07:30AM
Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer
(GlobeNewswire)
May-25-22 07:30AM
Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference
(GlobeNewswire) -6.32%
May-10-22 07:30AM
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
(GlobeNewswire) +9.80%
May-07-22 09:40AM
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
(Simply Wall St.)
Apr-21-22 09:09AM
9 Healthcare Stocks to Invest In Today According to Stanley Druckenmiller
(Insider Monkey)
Mar-10-22 07:30AM
Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
(GlobeNewswire) -7.62%
Mar-09-22 04:05PM
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
(GlobeNewswire) +6.49%
Mar-03-22 07:30AM
Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference
(GlobeNewswire) -5.36%
Feb-11-22 07:30AM
Sensei Biotherapeutics to Participate in Citis 2022 Virtual Immuno-Oncology Summit
(GlobeNewswire)
Jan-17-22 11:22AM
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insiders placed bullish bets worth US$1.0m in the last 12 months
(Simply Wall St.)
Jan-06-22 08:00AM
Sensei Biotherapeutics Announces Executive Promotions
(GlobeNewswire)
Dec-16-21 09:01AM
Sensei Biotherapeutics Named a Winner of Comparablys Best CEO Award
(GlobeNewswire)
Dec-13-21 04:01PM
Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
(GlobeNewswire)
Nov-19-21 04:02PM
Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
(GlobeNewswire) -5.69%
Nov-17-21 10:37AM
What Percentage Of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Do Insiders Own?
(Simply Wall St.) -5.10%
Nov-12-21 07:02AM
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
(GlobeNewswire) +11.09%
Nov-09-21 08:54AM
Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights
(GlobeNewswire)
Nov-03-21 09:01AM
Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021
(GlobeNewswire)
Oct-01-21 08:05AM
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
(GlobeNewswire)
Aug-17-21 01:56PM
Here's Why We're Not Too Worried About Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
(Simply Wall St.)
Aug-09-21 12:00PM
Sensei Biotherapeutics, Inc. (SNSE) Upgraded to Buy: Here's Why
(Zacks)
Aug-04-21 07:45AM
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
(GlobeNewswire)
Aug-02-21 08:01AM
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
(GlobeNewswire)
Jun-29-21 01:49PM
These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday
(Motley Fool) -15.97%
Jun-28-21 04:05PM
Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs
(GlobeNewswire)
May-19-21 05:03PM
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
(GlobeNewswire) +5.42%
May-12-21 07:41AM
Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update
(GlobeNewswire)
May-05-21 08:05AM
Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board
(GlobeNewswire)
May-04-21 07:18AM
What Percentage Of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Do Insiders Own?
(Simply Wall St.) -8.48%
Apr-05-21 08:00AM
Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors
(GlobeNewswire)
Mar-25-21 08:00AM
Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update
(GlobeNewswire)
Mar-22-21 08:00AM
Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index
(GlobeNewswire)
Mar-09-21 08:30AM
Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference
(GlobeNewswire) +7.74%
Mar-05-21 03:30PM
Oppenheimer: 2 Stocks That Could Climb Over 100%
(TipRanks)
Feb-10-21 04:55PM
Sensei Biotherapeutics Announces Closing of Initial Public Offering
(GlobeNewswire) -7.32%
Feb-09-21 11:08AM
Cambrian Biopharma announces $60M in financing to develop a pipeline of companies and therapeutics to treat diseases of aging, coupled with a unique operational strategy
(PR Newswire) -9.89%
Feb-05-21 05:26PM
The Wave of Biotech IPOs Continues. Here Are 7 Stocks That Hit the Market
(Barrons.com) +18.99%
Feb-04-21 05:56PM
A Busy Day for Biotech IPOs
(Barrons.com)
Feb-03-21 08:44PM
Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering
(GlobeNewswire)
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Celebi JohnPresident and CEOSep 11 '23Buy0.85500425111,311Sep 13 08:43 AM
Apeiron Investment Group Ltd.10% OwnerJun 01 '23Sale1.583,441,6615,437,8240Jun 02 05:03 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

ATAI

ATAI Life Sciences N.V.

Last Close
May 03 • 04:00PM ET
2.05
Dollar change
-0.08
Percentage change
-3.76 		%
ATAI ATAI Life Sciences N.V. daily Stock Chart
Held by: IBB VHT PSIL AVSC BIB IBBQ GWX
Index- P/E- EPS (ttm)-0.26 Insider Own30.44% Shs Outstand166.03M Perf Week6.22%
Market Cap343.19M Forward P/E- EPS next Y-0.77 Insider Trans-0.21% Shs Float116.45M Perf Month-18.33%
Income-40.23M PEG- EPS next Q-0.18 Inst Own7.89% Short Float5.07% Perf Quarter15.82%
Sales0.31M P/S1107.07 EPS this Y-210.00% Inst Trans11.11% Short Ratio3.68 Perf Half Y72.27%
Book/sh1.46 P/B1.40 EPS next Y0.65% ROA-13.43% Short Interest5.90M Perf Year7.89%
Cash/sh0.92 P/C2.22 EPS next 5Y- ROE-15.97% 52W Range1.02 - 2.85 Perf YTD45.39%
Dividend Est.- P/FCF- EPS past 5Y44.19% ROI-15.52% 52W High-28.07% Beta0.92
Dividend TTM- Quick Ratio9.22 Sales past 5Y-16.02% Gross Margin-71.02% 52W Low100.00% ATR (14)0.18
Dividend Ex-Date- Current Ratio9.22 EPS Y/Y TTM73.83% Oper. Margin-39927.07% RSI (14)51.36 Volatility8.88% 8.95%
Employees83 Debt/Eq0.07 Sales Y/Y TTM35.34% Profit Margin-12810.51% Recom1.00 Target Price9.50
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q59.38% Payout- Rel Volume0.73 Prev Close2.13
Sales Surprise-96.80% EPS Surprise20.90% Sales Q/Q-52.63% EarningsMar 28 BMO Avg Volume1.61M Price2.05
SMA20-2.87% SMA502.99% SMA20025.50% Trades Volume1,176,245 Change-3.76%
Date Action Analyst Rating Change Price Target Change
Apr-03-24Upgrade Maxim Group Hold → Buy $6
Nov-01-22Initiated Loop Capital Buy $18
Nov-30-21Initiated Maxim Group Buy $25
Nov-11-21Initiated ROTH Capital Buy $32
Oct-18-21Initiated H.C. Wainwright Buy $40
Sep-01-21Initiated Jefferies Buy $27
Jul-13-21Initiated RBC Capital Mkts Sector Perform $19
Jul-13-21Initiated Credit Suisse Outperform $25
Jul-13-21Initiated Cowen Outperform
Jul-13-21Initiated Citigroup Buy $26
Show Previous Ratings
Apr-24-24 07:00AM
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
(GlobeNewswire) -5.08%
Apr-17-24 07:00AM
atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
(GlobeNewswire) -7.91%
Mar-28-24 07:00AM
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
(GlobeNewswire) +10.06%
Mar-27-24 07:00AM
atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
(GlobeNewswire)
Mar-19-24 08:00AM
The Next Great Biotech Boom Has Arrived
(PR Newswire)
12:35PM Loading…
Mar-12-24 12:35PM
atai Life Sciences advances VLS-01 for treatment-resistant depression
(News Direct) -5.45%
Mar-04-24 08:00AM
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
(GlobeNewswire)
Feb-28-24 05:00PM
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
(GlobeNewswire)
Feb-06-24 05:00PM
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
(GlobeNewswire)
Jan-24-24 09:00AM
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
(PR Newswire)
Jan-07-24 10:15PM
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
(Market Exclusive)
Jan-05-24 08:54AM
Ecstasy-for-Medicine Advocate Raises $100 Million
(The Wall Street Journal)
08:00AM
Legalization Advocate MAPS Raises Money for Pharmaceutical Psychedelics
(The Wall Street Journal)
Jan-04-24 07:00AM
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
(GlobeNewswire) +14.67%
Jan-02-24 08:00AM
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
(GlobeNewswire) +19.86%
07:03AM Loading…
Nov-14-23 07:03AM
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
(GlobeNewswire) +9.13%
Oct-15-23 05:06PM
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
(Market Exclusive)
Oct-10-23 08:00AM
ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT
(PR Newswire)
Oct-06-23 04:05PM
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
(GlobeNewswire) -8.55%
Oct-02-23 04:13PM
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
(GlobeNewswire)
Sep-14-23 11:02PM
Insider Buying: Florian Brand Acquires 40,000 Shares of ATAI Life Sciences NV
(GuruFocus.com)
08:02AM
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
(GlobeNewswire)
Sep-06-23 04:01PM
atai Life Sciences to Participate in Upcoming September Investor Conferences
(GlobeNewswire)
Aug-10-23 06:59AM
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
(GlobeNewswire)
Aug-08-23 04:02PM
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
(GlobeNewswire)
Jun-28-23 09:37AM
Ecstasy-for-Medicine Advocate Seeks Cash Lifeline
(The Wall Street Journal) +7.89%
Jun-01-23 09:10AM
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
(GlobeNewswire)
06:59AM
atai Life Sciences to Participate in Upcoming June Investor Conferences
(GlobeNewswire)
May-11-23 06:59AM
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
(GlobeNewswire)
May-02-23 05:20PM
atai Life Sciences to Participate in Upcoming May Investor Conference
(GlobeNewswire)
06:59AM Loading…
Apr-28-23 06:59AM
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
(GlobeNewswire)
Apr-13-23 06:59AM
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
(GlobeNewswire) +9.89%
Apr-03-23 07:00AM
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
(Market Exclusive)
Mar-31-23 06:36AM
Daily Vickers Top Buyers & Sellers for 03/31/2023
(Argus Research) +13.12%
Mar-24-23 06:59AM
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
(GlobeNewswire) +5.04%
Mar-06-23 07:00AM
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
(GlobeNewswire)
Mar-01-23 04:01PM
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
(GlobeNewswire)
Jan-19-23 01:24PM
This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks
(Benzinga)
Jan-17-23 05:00AM
Trippy Trading: Top Psychedelic Stocks For 2023
(News Direct) +7.78%
Jan-09-23 07:00AM
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
(Market Exclusive) -9.34%
06:59AM
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
(GlobeNewswire)
Jan-06-23 10:38AM
Atai Life Sciences' Depression Candidate Faces Trial Setback, Shares Nosedive
(Benzinga) -30.80%
07:00AM
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
(GlobeNewswire)
Dec-23-22 06:59AM
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
(GlobeNewswire) -12.17%
Dec-19-22 06:59AM
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
(GlobeNewswire)
Dec-16-22 10:00AM
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
(GlobeNewswire)
Dec-01-22 07:39PM
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
(Market Exclusive) -5.38%
Nov-29-22 06:59AM
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
(GlobeNewswire)
Nov-17-22 07:00AM
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
(GlobeNewswire)
Nov-10-22 06:59AM
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
(GlobeNewswire) +7.72%
Nov-04-22 09:35AM
Women in Psychedelics Announces atai as Platinum Sponsors
(Business Wire)
Nov-01-22 12:00PM
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
(GlobeNewswire) +14.58%
07:00AM
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
(GlobeNewswire)
Oct-25-22 07:03AM
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
(GlobeNewswire)
Oct-20-22 06:59AM
atai Life Sciences Announces R&D Day Agenda
(GlobeNewswire) +7.60%
Oct-18-22 07:00AM
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
(GlobeNewswire)
Oct-13-22 09:21AM
IntelGenxs Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate
(GlobeNewswire)
Oct-12-22 07:00AM
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
(GlobeNewswire)
Oct-05-22 07:00AM
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
(GlobeNewswire)
Oct-04-22 07:00AM
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
(GlobeNewswire)
Sep-27-22 08:00AM
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
(GlobeNewswire) +7.96%
Sep-06-22 06:30PM
atai Life Sciences to Participate in September Investor Events
(GlobeNewswire)
Aug-15-22 07:35AM
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
(GlobeNewswire)
06:55AM
atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital
(GlobeNewswire)
Aug-01-22 06:59AM
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update
(GlobeNewswire) -8.03%
Jul-22-22 06:40AM
New Regulations for Psychedelics? Here's What Investors Need to Know
(Motley Fool)
Jul-12-22 12:10PM
Cathie Wood Watch: Ark Buys Big Into Biotech
(TheStreet.com)
Jun-30-22 06:59AM
atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
(GlobeNewswire)
Jun-17-22 06:59AM
Stephen Bardin to Join atai Life Sciences as CFO Designate
(GlobeNewswire)
Jun-16-22 05:59AM
atai Life Sciences to Participate in Upcoming June Healthcare Conferences
(GlobeNewswire) -6.04%
Jun-15-22 10:21AM
Here's Why We're Not Too Worried About Atai Life Sciences' (NASDAQ:ATAI) Cash Burn Situation
(Simply Wall St.)
May-16-22 06:55AM
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
(GlobeNewswire) +10.99%
May-06-22 11:20AM
Cathie Woods Latest Portfolio: 10 New Stock Picks in 2022
(Insider Monkey)
May-05-22 03:19PM
CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update
(GlobeNewswire) -8.45%
May-04-22 04:00AM
atai Life Sciences to Announce First-Quarter 2022 Financial Results
(GlobeNewswire)
Apr-19-22 03:22PM
EXCLUSIVE: ATAI Life Sciences Deploys Decentralized Approach To Transform Mental Health Treatments
(Benzinga)
12:26PM
atai Life Sciences to Participate in Upcoming April Investor Conference
(GlobeNewswire)
Apr-13-22 10:00AM
Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Health and Cancers
(GlobeNewswire) +5.49%
Mar-30-22 06:59AM
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
(GlobeNewswire)
Mar-23-22 06:59AM
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
(GlobeNewswire) -7.03%
Mar-21-22 01:08PM
atai Life Sciences to Participate in Upcoming March Investor Conferences
(GlobeNewswire) -6.55%
Feb-16-22 06:59AM
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
(GlobeNewswire) +5.76%
Feb-15-22 06:59AM
atai Life Sciences to Participate in Upcoming February Investor Conference
(GlobeNewswire) +5.17%
Jan-12-22 06:59AM
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
(GlobeNewswire)
Jan-10-22 01:03PM
atai Life Sciences to Participate in Upcoming January Investor Conference
(GlobeNewswire)
Dec-29-21 08:40AM
Implied Volatility Surging for ATAI Life Sciences (ATAI) Stock Options
(Zacks)
Dec-23-21 06:48AM
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health
(Zacks)
Dec-22-21 01:43PM
3 Psychedelic Stocks to Play the Shroom Boom
(Zacks) -6.12%
Dec-17-21 07:30AM
Armada Acquisition Corp. I to acquire Rezolve Mobile Engagement Platform in $2bn deal
(GlobeNewswire) +5.41%
Dec-16-21 06:59AM
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospitals Center for the Neuroscience of Psychedelics
(GlobeNewswire) +11.14%
Dec-15-21 04:19PM
Psychedelic Drug Firms Billionaire Backer Will Hold Onto Stake
(Bloomberg) -31.94%
06:57AM
Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements
(GlobeNewswire)
Dec-14-21 07:30AM
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
(GlobeNewswire) -9.07%
Dec-13-21 06:59AM
atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index
(GlobeNewswire)
Dec-09-21 10:30AM
atai Life Sciences launches TryptageniX to further expand atais robust intellectual property portfolio and strengthen atai's supply chain
(GlobeNewswire) -5.10%
Dec-06-21 07:01AM
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
(Market Exclusive)
Nov-29-21 07:00AM
atai Life Sciences Increases its Ownership Position in COMPASS Pathways
(GlobeNewswire)
Nov-15-21 06:59AM
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
(GlobeNewswire) -13.87%
Nov-08-21 08:30AM
atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
(GlobeNewswire)
Nov-05-21 04:30PM
atai Life Sciences to Participate in Upcoming November Investor Conferences
(GlobeNewswire)
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rao SrinivasSee RemarksApr 02 '24Sale1.8561,640114,034113,360Apr 04 06:11 PM
Kirpekar SahilChief Business OfficerApr 02 '24Sale1.8535,80166,23264,199Apr 04 06:11 PM
Johnson Anne NagengastChief Financial OfficerApr 02 '24Sale1.8527,41050,70873,590Apr 04 06:11 PM
Brand FlorianSee RemarksNov 16 '23Buy1.1620,00023,120130,000Nov 20 09:17 AM
Brand FlorianSee RemarksSep 13 '23Buy1.4540,00057,968110,000Sep 14 04:30 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.